Teva Rocked After Earnings (TEVA)

Shares of Teva Pharmaceuticals TEVA are falling on Tuesday after the company released its Q4 earnings results. The Israeli company reported adjusted net EPS of $1.25, which missed analysts' consensus estimates of $1.28. For fiscal 2011, TEVA sees earnings per share between $4.90 and $5.20, which is also below Wall Street EPS consensus estimates of $5.28. TEVA's Q4 revenues were $4.42 billion versus expectations of $4.64 billion. The stock has lost 6.53% to $51.39 during Tuesday's trading session. Despite its high quality and strong analyst support, TEVA has not been able to gain any traction. The stock is down almost 10% in the last year, and is only up 1% over the last 3 months despite a broad market rally.